Financial Snapshot

Revenue
$80.87M
TTM
Gross Margin
Net Earnings
-$17.91M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1843.61%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$257.3M
Q3 2024
Cash
Q3 2024
P/E
-10.57
Nov 29, 2024 EST
Free Cash Flow
-$8.739M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $2.805M $6.342M $19.16M $8.823M $0.00 $0.00 $0.00
YoY Change -55.77% -66.9% 117.19%

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $2.805M $6.342M $19.16M $8.823M $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $41.67M $41.69M $30.52M $21.39M $13.15M $8.310M $4.500M
YoY Change -0.06% 36.63% 42.66% 62.66% 58.24% 84.67%
% of Gross Profit
Research & Development $71.80M $76.78M $69.70M $59.04M $71.07M $25.18M $18.49M
YoY Change -6.49% 10.16% 18.05% -16.93% 182.21% 36.2%
% of Gross Profit
Depreciation & Amortization $2.200M $2.400M $2.500M $2.400M $2.053M $1.345M $720.0K
YoY Change -8.33% -4.0% 4.17% 16.9% 52.64% 86.81%
% of Gross Profit
Operating Expenses $113.5M $118.9M $100.2M $80.43M $84.22M $33.50M $22.99M
YoY Change -4.57% 18.65% 24.6% -4.49% 151.41% 45.71%
Operating Profit -$110.7M -$112.6M -$81.05M -$71.61M -$84.22M
YoY Change -1.69% 38.87% 13.19% -14.97%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $13.33M $2.690M $207.0K $792.0K $1.540M $520.0K $0.00
YoY Change 395.5% 1199.52% -73.86% -48.57% 196.15%
% of Operating Profit
Other Income/Expense, Net $13.33M $2.690M $207.0K $790.0K $30.00K $390.0K $30.00K
YoY Change 395.5% 1199.52% -73.8% 2533.33% -92.31% 1200.0%

Income/Loss

Pretax Income

Income Tax

No data

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$97.34M -$109.9M -$80.85M -$70.82M -$82.68M -$32.59M -$22.96M
YoY Change -11.41% 35.9% 14.16% -14.34% 153.7% 41.94%
Income Tax
% Of Pretax Income
Net Earnings -$97.34M -$109.9M -$80.85M -$70.82M -$82.68M -$32.59M -$22.96M
YoY Change -11.41% 35.9% 14.16% -14.34% 153.7% 41.93%
Net Earnings / Revenue -3470.05% -1732.43% -421.89% -802.66%
Basic Earnings Per Share -$1.59 -$2.44 -$2.29
Diluted Earnings Per Share -$1.59 -$2.44 -$2.286M -$2.794M -$3.650M -$1.462M -$1.030M

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

No data

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $236.2M $202.9M $218.2M $112.9M $96.70M $72.80M $400.0K
YoY Change 16.41% -6.99% 93.23% 16.75% 32.83% 18100.0%
Cash & Equivalents $25.56M $35.10M $35.41M $57.10M $96.70M $72.80M $400.0K
Short-Term Investments $210.7M $167.8M $182.8M $55.90M
Other Short-Term Assets $3.729M $3.517M $3.726M $3.900M $3.300M $800.0K $800.0K
YoY Change 6.03% -5.61% -4.46% 18.18% 312.5% 0.0%
Inventory
Prepaid Expenses
Receivables $2.249M $1.081M $4.110M $2.700M $100.0K $100.0K $0.00
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $400.0K $0.00
Total Short-Term Assets $242.2M $207.5M $226.0M $119.5M $100.1M $74.10M $1.300M
YoY Change 16.71% -8.18% 89.12% 19.38% 35.09% 5600.0%
Property, Plant & Equipment $12.39M $15.97M $7.368M $8.400M $9.200M $10.50M $2.900M
YoY Change -22.4% 116.73% -12.29% -8.7% -12.38% 262.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.103M $3.197M $1.634M $1.700M $1.200M $1.100M $100.0K
YoY Change -2.94% 95.65% -3.88% 41.67% 9.09% 1000.0%
Total Long-Term Assets $15.50M $19.17M $9.002M $10.10M $10.30M $11.70M $3.000M
YoY Change -19.15% 112.91% -10.87% -1.94% -11.97% 290.0%
Total Assets $257.7M $226.7M $235.0M $129.6M $110.4M $85.80M $4.300M
YoY Change
Accounts Payable $2.757M $3.638M $4.788M $4.100M $2.200M $1.300M $1.700M
YoY Change -24.22% -24.02% 16.78% 86.36% 69.23% -23.53%
Accrued Expenses $10.52M $12.05M $9.157M $7.200M $5.400M $2.200M $1.100M
YoY Change -12.67% 31.57% 27.18% 33.33% 145.45% 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $100.0K $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $13.68M $16.73M $19.20M $26.70M $12.10M $4.200M $2.800M
YoY Change -18.24% -12.89% -28.09% 120.66% 188.1% 50.0%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $8.826M $11.02M $4.262M $7.700M $11.10M $5.500M $200.0K
YoY Change -19.89% 158.52% -44.65% -30.63% 101.82% 2650.0%
Total Long-Term Liabilities $8.826M $11.02M $4.262M $7.700M $11.10M $5.500M $200.0K
YoY Change -19.89% 158.52% -44.65% -30.63% 101.82% 2650.0%
Total Liabilities $22.50M $27.74M $23.46M $34.40M $23.30M $9.800M $3.000M
YoY Change -18.89% 18.25% -31.8% 47.64% 137.76% 226.67%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding 61.31K 44.99K 35.36K
Diluted Shares Outstanding 61.31K 44.99K 35.36K
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $189.32 Million

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2019-07-18. The firm is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

Industry: Pharmaceutical Preparations Peers: Bakhu Holdings, Corp. Esperion Therapeutics, Inc. Evolus, Inc. OCULAR THERAPEUTIX, INC JOHNSON & JOHNSON Liquidia Corp Phathom Pharmaceuticals, Inc. Rani Therapeutics Holdings, Inc. Tarsus Pharmaceuticals, Inc.